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When will nebulized chemotherapy come of age? 
In the 1970s nebulized chemotherapy was a newly 
available technique offering hope to the rapidly 
deteriorating cystic fibrosis patient. It was quickly 
put to use by the clinician, and escaped its baptism of 
fire. Can the time-honoured clinical pharmacokinetic 
model restore scientific order to the process? 
Almost every month a new antibiotic is added to 
the clinician’s arsenal. ‘uost of these antibiotics are 
assessed by clinical pharmacologists before they are 
launched. Careful pharmacokinetic and pharmaco- 
dynamic studies are performed. The antibiotic is then 
ready for general use. 
Most of these antibiotics are for use by the con- 
ventional routes of administration: oral, intramuscu- 
lar, or intravenous. 
With nebulized antibiotics, however, the story is 
very different. Although in widespread use, most 
were never designed for the purpose. Thirteen years 
have elapsed since the first randomized, placebo- 
controlled trial proved their efficacy (1). We continue, 
however, to prescribe the commercially available 
intravenous tobramycin for nebulizer use, although it 
contains sodium metabisulphite, an agent with estab- 
lished bronchoconstricting properties when adminis- 
tered by the inhaled route (2). Colistin, the other 
popular nebulized antibiotic, is also licensed for 
intramuscular and intravenous use alone. Are we 
justified in prescribing products licensed for 
parenteral use, for the purposes of inhaled adminis- 
tration? Surely nebulized antibiotic therapy should 
by now have come of age, and earned its rightful 
place in the formulary. 
The apathy extends much further. A good text- 
book of pharmacology (3) elucidates the principles 
ofphannacokinetics that allow us to formulate the 
appropriate drug dose for adult and child. The 
principles of pharmacokinetics in relation to orally 
administered drugs, for example, involve the pro- 
cesses of absorption, distribution, biotransformation 
and excretion. The first two processes determine 
‘bioavailability’, describing the factors that affect the 
passage of the drug from its site of administration to 
its site of action, or a biological fluid from which it 
has access to its site of action. Biotransformation for 
an orally administered drug describes the process of 
inactivation at or before the drug reaches its site of 
action. Oxidation, reduction and hydrolysis in the 
liver and other viscera, for example, may partially 
inactivate the drug en route to its site of action. 
0954-611 l/94/040245+03 $08.00/O 
Finally, excretion leads to its elimination from the 
organism. A study of the above processes for an 
orally administered drug allows the estimation of a 
‘dose’ for the human subject, based on the rational 
principles of science. Pharmacodynamic studies 
(clinical trials) then follow, to evaluate the efficacy 
and safety of the drug for the dose determined on the 
principles of pharmacokinetics. 
In the field of nebulized chemotherapy empiricism 
has prevailed instead. In the first double-blind, ran- 
domized trial of aerosolized antibiotics referred to 
above, the authors provide no justification for their 
choice of dose (1 g carbenicillin and 80 mg of gen- 
tamicin). Polypharmacy of this nature would in any 
case have been unacceptable in most other pharma- 
codynamic studies to evaluate a drug or a form of 
treatment. A very large number of inadequately 
designed studies followed. A variety of nebulized 
antimicrobial agents were used to deal with a given 
bacteriological scenario, in doses chosen with total 
empiricism, varying up to lo-fold (4,5). Add to this 
the almost five-fold variation in output amongst 
nebulizer systems (6), and little chance remains of 
relating dose to response. As might be expected, 
however, most of these trials suggested clinical ben- 
efit for cystic fibrosis patients with Pseudomonas 
aeruginosa colonization, as a prophylactic against 
Pneumocystis carinii pneumonia in the acquired 
immunodeficiency syndrome and a variety of other 
conditions. As a result, patients across the world 
continue to receive widely differing pulmonary doses 
of a variety of nebulized chemotherapeutic agents on 
a regular basis. 
To find a way out of the quagmire, let us hypoth- 
esize that we can adapt the clinical pharmacokinetic 
model enunciated above to evaluate nebulized 
chemotherapy, in order to develop a rational dose for 
the individual patient. If all the steps which comprise 
the clinical pharmacokinetic model for an orally 
administered drug are taken for our nebulized agent, 
we should along the same (time-tested) lines be able 
to predict an appropriate ‘dose’ for the human sub- 
ject. The development of a scientifically determined 
dose (instead of 40 or 120mg off the top of the 
physician’s head), and the description of the factors 
which influence its variation amongst normal and 
diseased individuals should lead us into pharmaco- 
dynamic studies more likely to improve efficacy and 
safety. Let us now relate the ‘inhaled drug scenario’ 
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to the above model, following the sequence of 
bioavailability (which includes absorption and 
distribution), biotransformation, and excretion. 
Bioavailability 
A method for accurately quantifying the amount 
of drug deposited to the lung and its specific regions 
has been described (7) and has been used to quantify 
the pulmonary dose in patients with cystic fibrosis 
(8,9) and the acquired immunodeficiency syndrome 
(6). It involves tagging the drug with a radiolabel, 
and imaging the distribution of the radiolabel in the 
lung immediately after nebulization. The radiation 
dose is comparable to that from a chest radiograph, 
and ethical justification should not be difficult to 
obtain in view of the considerable long-term clinical 
benefit. 
Bioavailability for an aerosolized drug would thus 
be determined by the factors which affect the passage 
of the antibiotic aerosol as it courses from its site of 
administration (mouth/nose) to its site of action, the 
lungs. While the effects of particle size and airways 
obstruction have been studied, air entrainment from 
the discrepancy between nebulizer flow and the 
inspiratory flow rate of the subject (10) is of funda- 
mental importance, and require to be taken into 
account of without delay to achieve optimal drug 
delivery in clinical practice. Almost without doubt, 
other such factors will continue to be unearthed in 
the foreseeable future, and the only way to estimate 
the bioavailability of a nebulized chemotherapeutic 
agent with reasonable accuracy (at our current state 
of knowledge) is to administer the drug with its 
radio-tag, and visualize it immediately after with the 
help of an appropriately adjusted gamma camera. 
The accurate quantitation of the dose of nebulized 
chemotherapeutic agent delivered to the site of action 
is the first step in estimating correct dose for a set 
of patients with a relatively similar pattern of 
respiratory disease. 
Biotransformation 
The drug delivered to its site of action in the 
respiratory tract may be rendered inactive. The next 
step in studying the pharmacokinetics of nebulized 
chemotherapy would be to focus on this problem. 
Although the chemical processes may be different, 
the concept of biotransformation still applies. 
Biotransformation for aerosolized drugs on their way 
to their site of action in the cystic fibrosis lung is 
almost certainly of fundamental importance. In vitro, 
tobramycin is equally bactericidal only in 25fold 
concentrations in the presence of CF sputum as 
without; ionic binding and antagonism has been 
postulated as one of several mechanisms leading to 
this inactivation (11,12). 
The epithelial lining fluid is the target fluid, with 
reference to nebulized antibiotic therapy in cystic 
fibrosis. Ideally, one would like to estimate the con- 
centration of the aerosol-administered antibiotic in 
this fluid, assess its minimum bactericidal concen- 
tration in the same fluid, and adjust dose accordingly. 
A quantitative assessment of this fluid is difficult, 
although perhaps not impossible (13). In a study 
involving young cystic fibrosis patients administered 
nebulized antibiotics, we used sputum instead, and 
attempted to relate tobramycin levels in this fluid to 
minimum bactericidal concentrations for the anti- 
biotic in CF sputum in vitro (9). As the dose of drug 
delivered to the lungs is quantifiable, a method for 
quantifying respiratory fluid volume and content 
may help determine with greater accuracy the anti- 
biotic concentrations achieved following nebuliz- 
ation. It should then be possible to investigate the 
dose-effect relationship for a particular drug, in 
order to achieve maximal effect with this form of 
therapy. 
Excretion 
Excretion, the final step in the pharmacokinetic 
process, leads to the removal of the active drug from 
the affected site. In the context of pulmonary aero- 
sols, it relates to mucociliary clearance and passive or 
carrier-mediated (14) absorption from the respiratory 
fluid, which determine how long the active drug 
remains at its site of action. Both processes are 
abnormal (15) but have been inadequately studied 
for pathological states of the lung (16). The propor- 
tion of drug systemically absorbed to that cleared 
varies widely; if high, a part of the systemically 
absorbed dose may be recycled to the respiratory 
fluid. 
The pharmacokinetic model has successfully evalu- 
ated systemically administered drugs, in preparation 
for pharmacodynamic studies. It appears that the 
model can be adapted to fulfill a similar role in 
nebulized medicine, by establishing: 
1. the quantity of drug reaching the proposed site of 
action, 
2. the factors influencing this deposition, 
3. the proportion of the drug remaining active 
following deposition, and 
4. the concentration of this active drug in the target 
fluid, and how this relates to the minimum inhibi- 
tory and bactericidal concentrations for the drug. 
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This should allow us to determine an accurate 5. 
‘dose’ for each class of patients (as in conventional 
pharmacotherapeutics involving oral or parenterally 
administered drugs) and thus turn from empiricism 6. 
to definition when prescribing inhaled drugs, in par- 
ticular antimicrobials, for our paediatric and adult 
patients with cystic fibrosis and other forms of 
chronic lung disease. 
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